Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

Return to program book search

Session Information

FRM F086 - BCC in the Age of Targeted Therapy

Open admission to eligible categories, no tuition or ticket


Date: Sunday, March 03

CME Credits: 2.00

Location: Room D235/236

Time: 1:00 PM - 3:00 PM

Director: Aleksandar Sekulic, MD, FAAD


  • Nicole Basset-Seguin, MD, PhD - Handout
  • David R. Bickers, MD, FAAD
  • Anne Lynn S. Chang, MD, FAAD
  • Steven A. Nelson, MD, FAAD

Learning Objectives:
Following this course, the attendee should be able to:

  • Review clinical features and pathogenesis of basal cell carcinoma.
  • Describe the role of the hedgehog signaling pathway in basal cell carcinoma and its implication for treatment of BCC.
  • Evaluate the utility of targeted therapy in treatment of BCC and discuss its benefits and challenges.

BCC, the most common human cancer, is surgically curable in most cases. However, a fraction of BCC tumors may progress to locally advanced (laBCC) or even metastatic (mBCC) stage. Historically, such patients faced dismal therapeutic choices. Recent progress in understanding the molecular pathogenesis of BCC has enabled development of novel targeted therapies. This forum will provide an update on the targeted treatments in BCC with a particular emphasis on the inhibition of the “Hedgehog” signaling pathway. Clinical progress and the challenges associated with targeted therapy in BCC will be reviewed and future directions explored.


Sunday, March 03
1:00 PMIntroduction / Dr. Sekulic
1:05 PMClinical spectrum of BCC / Dr. Basset-Seguin
1:25 PMThe Hedgehog Pathway / Dr. Nelson
1:45 PMHedgehog pathway inhibition in a BCC / Dr. Chang
2:05 PMHedgehog pathway inhibition in BCNS / Dr. Bickers
2:30 PMChallenges and future directions / Dr. Sekulic
2:45 PMPanel Discussion / All faculty